Dr. Liliya Golas, MD

Dr. Golas practices at Martel Eye Institute in Rancho Cordova, California.

Dr. Golas' NPI, 1346509205, was assigned on May 14, 2012. Dr. Golas graduated from Stanford University School Of Medicine in 2012. Dr. Golas holds California license A156865.

Dr. Golas' primary practice is Martel Eye Institute, at 11216 Trinity River Drive, Rancho Cordova, CA 95670. The practice phone is (916) 631-7868.

Dr. Golas' primary practice is Martel Eye Institute in Rancho Cordova, California. Dmand AI also links Dr. Golas to 1 physician office, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Golas practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Golas' primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Golas is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Golas' licenses on file in 3 states: California, Illinois and Colorado.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, eyelid inflammation, glaucoma, glaucoma surgery and hypertensive retinopathy among the conditions Dr. Golas treats.

CMS data shows 15,540 Medicare services from Dr. Golas across 17 procedure codes in 2024, for 730 Medicare patients. Medicare paid $911,056 for them. Every service was in an office.

CMS counts 730 Medicare patients who saw Dr. Golas in 2024. The largest group is 65 to 74, with 341 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 81% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Golas' median patient age at 66, with 59% women.

In 2024, Dr. Golas wrote 2,243 Medicare Part D claims for 464 patients. 68% of them were for generic drugs. CMS names the drug for 2,172 of them, across 24 drugs with 11 or more claims each, at $349,879 in total drug cost. In 2023, CMS named 1,906 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Golas for performance year 2024, reported individually. Dr. Golas accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 12 papers to Dr. Golas, published from 2011 to 2023. The most frequent topics are Plastic Surgery Procedures and Visual Acuity. Dr. Golas has published most often in Ophthalmic Plast Reconstr Surg. Dr. Golas' most frequent co-authors are Michael Pr Blair, FNP-C, Seenu M. Hariprasad and James B. Martel, MD.

CMS Open Payments shows 318 general payments to Dr. Golas from 29 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 56% of the total. Novartis Pharmaceuticals Corporation paid the most, $3,082.

Dr. Golas graduated from Stanford University School Of Medicine in 2012.

Dr. Golas is in network with 7 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.